Population
Patients with paroxysmal supraventricular tachycardia
Design
Review
Authors
Loading...
Alerts clinicians to screen for accessory pathways in PSVT before AV nodal blockers; leaves open prospective validation of risk-reduction strategies.
It is crucial to identify accessory pathways in patients with paroxysmal supraventricular tachycardia to avoid inappropriate drug therapy that could precipitate ventricular fibrillation.
Anthony C. Caruso (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: